{
    "Trade/Device Name(s)": [
        "Total Bilirubin",
        "Total Bilirubin Reagent"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K060574",
    "Predicate Device Reference 510(k) Number(s)": [
        "K910591"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG",
        "MQM",
        "JIT"
    ],
    "Summary Letter Date": "March 14, 2019",
    "Summary Letter Received Date": "March 6, 2006",
    "Submission Date": "March 3, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Total Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AEROSET System",
        "ARCHITECT c8000 System",
        "Hitachi 717 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric chemical reaction",
        "Diazo reagent method"
    ],
    "Methodologies": [
        "In vitro quantitative analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Total Bilirubin in vitro diagnostic assay using colorimetric diazo reagent for quantitation of total bilirubin in serum or plasma",
    "Indications for Use Summary": "Quantitative determination of total bilirubin in human serum or plasma for diagnosing and treating liver, hemolytic, and metabolic disorders, including assessment of bilirubin levels in neonates to indicate risk of bilirubin encephalopathy",
    "fda_folder": "Clinical Chemistry"
}